Yooyoung signs marketing agreement for novel combination of pravastatin and fenofibrate

Published: 2010-02-05 06:56:00

Updated: 2010-02-05 06:56:00

Yooyoung Pharm says it has recently entered into an exclusive agreement with Belgium based 'LABORATOIRES SMB S.A. to locally market Pravafen, a combination of fenofibrate and pravastatin to treat mixed dyslipidemia.

Currently, Smb completed Phase III clinical trials for Pravafen and expects to...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK